Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival

British Journal of Haematology, 05/11/2012

The long–term follow–up confirmed the achievement, by the combined treatment, of fairly long–lasting erythroid response in the majority of MDS patients with unfavourable prognostic features for response to erythropoietin: this translated in a survival benefit that was independent from other prognostic features.

Print Article Summary Cat 2 CME Report